Disease Susceptibility to ST11 complex meningococci bearing serogroup C or W135 polysaccharide capsules, North America

Emerging Infectious Diseases

Volumn 10, Issue 10, 2004, Pages 1812-1815

  Pollard, Andrew J ^a,d,e   Ochnio, Jan ^b   Ho, Margaret ^b   Callaghan, Martin ^a   Bigham, Mark ^c   Dobson, Simon ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c CANADIAN BLOOD SERVICES   (Canada)

^d JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIAL STRAIN; BLOOD GROUP TYPING; CHILD; COMPLEX FORMATION; CONTROLLED STUDY; DISEASE PREDISPOSITION; EPIDEMIC; HOUSEKEEPING GENE; HUMAN; IMMUNITY; INCIDENCE; INFANT; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NONHUMAN; NORMAL HUMAN; NORTH AMERICA; SERUM BACTERICIDAL ACTIVITY; ST11 GENE;

EID: 4844227592     PISSN: 10806040     EISSN: None     Source Type: Journal    
DOI: 10.3201/eid1010.040335     Document Type: Article

References (20)

1. Heist GD, Solis-Cohen S, Solis-Cohen M. A study of the virulence of meningococci for man and of human susceptibility to meningococcic infection. J Immunol. 1922;7:1-33.
2. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningocoecus. II. Development of natural immunity. J Exp Med. 1969;129:1327-48.
3. Whalen CM, Hockin JC, Ryan A, Ashton F. The changing epidemiology of invasive meningococcal disease in Canada, 1985 through 1992. Emergence of a virulent clone of Neisseria meningitidis. JAMA. 1995;273:390-4.
4. Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol. 2003;10:780-6.
5. Chan M-S, Jolley K. Neisseria MLST home page [cited 9 Aug 2004], Available from http://pubmlst.org/neisseria
6. Borrow R, Carlone GM. Serogroup B and C bactericidal assays. In: Pollard AJ, Maiden MCJ, editors. Meningococcal vaccines. Totowa (NJ): Humana Press Inc.; 2001. p. 289-304.
7. Borrow R, Andrews N, Goldblatt D, Miller E. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect Immun. 2001;69:1568-73.
8. Pollard AJ, Scheifele D. Meningococcal disease and vaccination in North America. J Paediatr Child Health. 2001;37:20-7.
9. Trotter C, Borrow R, Andrews N, Miller E. Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the pre-vaccination era. Vaccine. 2003;21:1094-8.
10. Jones GR, Williams JN, Christodoulides M, Jolley K, Heckels JE. Lack of immunity in university students before an outbreak of serogroup C meningococcal infection. J Infect Dis. 2000;181:1172-5.
11. Public Health Laboratory Service. Meningococcal disease associated with the Haj - update. Commun Dis Rep CDR Wkly. 2000;10:169.
12. Taha MK, Parent Du Chatelet I, Schlumberger M, Sanou I, Djibo S, de Chabalier F, et al. Neisseria meningitidis serogroups W135 and A were equally prevalent among meningitis cases occurring at the end of the 2001 epidemics in Burkina Faso and Niger. J Clin Microbiol. 2002;40:1083-4.
13. Evans JR, Artenstein MS, Hunter DH. Prevalence of meningococcal serogroups and description of three new groups. Am J Epidemiol. 1968;87:643-6.
14. Aguilera JF, Perrocheau A, Meffre C, Hahne S. Outbreak of serogroup W135 meningococcal disease after the Hajj pilgrimage, Europe, 2000. Emerg Infect Dis. 2002;8:761-7.
15. Hahne SJ, Gray SJ, Aguilera J-F, Crowcroft NS, Nicols T, Kaczmarski EB, et al. W135 meningococcal disease in England and Wales associated with Hajj 2000 and 2001. Lancet. 2002;359:582-3.
16. Mayer LW, Reeves MW, Al-Hamdan N, Sacchi CT, Taha MK, Ajello GW, et al. Outbreak of W135 meningococcal disease in 2000: not emergence of a new W135 strain but clonal expansion within the electophoretic type-37 complex. J Infect Dis. 2002;185:1596-605.
17. World Health Organization. Meningococcal disease, serogroup W135, Burkina Faso. Preliminary report, 2002. Wkly Epidemiol Rec. 2002;77:152-5.
18. Stefanelli P, Fazio C, Neri A, Sofia T, Mastrantonio P. First report of capsule replacement among electrophoretic type 37 Neisseria meningitidis strains in Italy. J Clin Microbiol. 2003;41:5783-6.
19. Wang JF, Caugant DA, Morelli G, Koumare B, Achtman M. Antigenic and epidemiologic properties of the ET-37 complex of Neisseria meningitidis. J Infect Dis. 1993;167:1320-9.
20. Vazquez J. Experiences with meningococcal vaccines. Paper presented at: European Society for Paediatric Infectious Disease, 2004; Tampere, Finland.